

Giuseppe Barbaro

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/11774532/giuseppe-barbaro-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

93
papers

3,370
citations

34
h-index

56
g-index

98
ext. papers

3,694
ext. citations

6.5
avg, IF

5.27
L-index

#	Paper	IF	Citations
93	Blood SIRT1 Shows a Coherent Association with Leptin and Adiponectin in Relation to the Degree and Distribution of Adiposity: A Study in Obesity, Normal Weight and Anorexia Nervosa. <i>Nutrients</i> , 2020 , 12,	6.7	2
92	Epicardial adipose tissue feeding and overfeeding the heart. <i>Nutrition</i> , 2019 , 59, 1-6	4.8	31
91	Inverse Association of Circulating SIRT1 and Adiposity: A Study on Underweight, Normal Weight, and Obese Patients. <i>Frontiers in Endocrinology</i> , 2018 , 9, 449	5.7	13
90	Cardiovascular disease burden among human immunodeficiency virus-infected individuals. <i>International Journal of Cardiology</i> , 2018 , 265, 195-203	3.2	15
89	Epicardial adipose tissue and signs of metabolic syndrome in children. <i>Eating and Weight Disorders</i> , 2016 , 21, 269-76	3.6	6
88	Severe growth hormone deficiency and empty sella in obesity: a cross-sectional study. <i>Endocrine</i> , 2015 , 49, 503-11	4	12
87	Epicardial fat thickness and nonalcoholic fatty liver disease in obese subjects. <i>Obesity</i> , 2014 , 22, 332-6	8	56
86	Association of epicardial fat thickness with the severity of obstructive sleep apnea in obese patients. <i>International Journal of Cardiology</i> , 2013 , 167, 2244-9	3.2	43
85	Relationships between body fat distribution, epicardial fat and obstructive sleep apnea in obese patients with and without metabolic syndrome. <i>PLoS ONE</i> , 2012 , 7, e47059	3.7	49
84	Human immunodeficiency virus & cardiovascular risk. <i>Indian Journal of Medical Research</i> , 2011 , 134, 898-903	9.3	16
83	Prothrombotic effects of contraceptives. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3490-6	3.3	11
82	Patent foramen ovale and thromboembolic complications. <i>Current Pharmaceutical Design</i> , 2010 , 16, 3497-502	3.5	6
81	Heart and HAART: Two sides of the coin for HIV-associated cardiology issues. <i>World Journal of Cardiology</i> , 2010 , 2, 53-7	2.1	19
80	Cardiovascular complications in the acquired immunodeficiency syndrome. <i>Revista Da Associação Médica Brasileira</i> , 2009 , 55, 621-30	1.4	10
79	Metabolic syndrome associated with HIV and highly active antiretroviral therapy. <i>Current Diabetes Reports</i> , 2009 , 9, 37-42	5.6	41
78	Impairment of diastolic function in adult patients affected by osteogenesis imperfecta clinically asymptomatic for cardiac disease: casualty or causality?. <i>International Journal of Cardiology</i> , 2009 , 131, 200-3	3.2	29
77	New options in the treatment of lipid disorders in HIV-infected patients. <i>Open AIDS Journal</i> , 2009 , 3, 31-7	0.6	12

76	Relation of epicardial fat and alanine aminotransferase in subjects with increased visceral fat. <i>Obesity</i> , 2008 , 16, 179-83	8	43
75	Threshold values of high-risk echocardiographic epicardial fat thickness. <i>Obesity</i> , 2008 , 16, 887-92	8	178
74	Chronic pharmacological treatment in takotsubo cardiomyopathy. <i>International Journal of Cardiology</i> , 2008 , 127, 121-3	3.2	42
73	Treatment of Tako-tsubo cardiomyopathy. <i>International Journal of Cardiology</i> , 2008 , 130, 475-6	3.2	6
72	Relationship of epicardial fat thickness and fasting glucose. <i>International Journal of Cardiology</i> , 2008 , 128, 424-6	3.2	79
71	Pharmacological therapy in children with atrial fibrillation and atrial flutter. <i>Current Pharmaceutical Design</i> , 2008 , 14, 770-5	3.3	10
70	Cardiac metabolism in myocardial ischemia. <i>Current Pharmaceutical Design</i> , 2008 , 14, 2551-62	3.3	77
69	The role of statins in preventing the progression of congestive heart failure in patients with metabolic syndrome. <i>Current Pharmaceutical Design</i> , 2008 , 14, 2605-12	3.3	6
68	Clinical findings of Takotsubo cardiomyopathy: results from a multicenter international study. <i>Journal of Cardiovascular Medicine</i> , 2008 , 9, 239-44	1.9	25
67	Relation of subepicardial adipose tissue to carotid intima-media thickness in patients with human immunodeficiency virus. <i>American Journal of Cardiology</i> , 2007 , 99, 1470-2	3	83
66	Visceral fat as target of highly active antiretroviral therapy-associated metabolic syndrome. <i>Current Pharmaceutical Design</i> , 2007 , 13, 2208-13	3.3	43
65	Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. <i>Current HIV Research</i> , 2007 , 5, 129-37	1.3	69
64	Editorial [Hot Topic: New Potential Pharmaceutical Targets of Metabolic Syndrome (Executive Editors: Gianluca Iacobellis and Giuseppe Barbaro)]. <i>Current Pharmaceutical Design</i> , 2007 , 13, 2146-2147	3.3	
63	Epicardial adipose tissue is related to carotid intima-media thickness and visceral adiposity in HIV-infected patients with highly active antiretroviral therapy-associated metabolic syndrome. <i>Current HIV Research</i> , 2007 , 5, 275-9	1.3	47
62	Chronic sildenafil in men with diabetes and erectile dysfunction. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2007 , 3, 451-64	5.5	24
61	HIV infection and cancer in the era of highly active antiretroviral therapy (Review). <i>Oncology Reports</i> , 2007 , 17, 1121-6	3.5	54
60	Phosphodiesterase 5 inhibitors--drug design and differentiation based on selectivity, pharmacokinetic and efficacy profiles. <i>Current Pharmaceutical Design</i> , 2006 , 12, 3459-65	3.3	50
59	Takotsubo-like left ventricular dysfunction in an HIV-infected patient. <i>Current HIV Research</i> , 2006 , 4, 239-41	1.3	11

58	Metabolic and cardiovascular complications of highly active antiretroviral therapy for HIV infection. <i>Current HIV Research</i> , 2006 , 4, 79-85	1.3	64
57	Highly active antiretroviral therapy-associated metabolic syndrome and cardiovascular risk. <i>Chemotherapy</i> , 2006 , 52, 161-5	3.2	27
56	Cardiovascular monitoring of HIV-infected patients. <i>Journal of Cardiovascular Medicine</i> , 2006 , 7, 379; author reply 380	1.9	2
55	Highly active antiretroviral therapy-associated metabolic syndrome: pathogenesis and cardiovascular risk. <i>American Journal of Therapeutics</i> , 2006 , 13, 248-60	1	55
54	HIV-associated myocarditis. <i>Heart Failure Clinics</i> , 2005 , 1, 439-48	3.3	8
53	HIV-associated cardiomyopathy etiopathogenesis and clinical aspects. <i>Herz</i> , 2005 , 30, 486-92	2.6	23
52	Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. <i>Current Pharmaceutical Design</i> , 2005 , 11, 1805-43	3.3	199
51	Methadone and QT prolongation in HIV-infected patients. <i>American Journal of Cardiology</i> , 2004 , 94, 147-8	3	6
50	HAART drugs induce mitochondrial damage and intercellular gaps and gp120 causes apoptosis. <i>Cardiovascular Toxicology</i> , 2004 , 4, 327-37	3.4	46
49	Regarding: Right ventricular cardiac dysfunction in HIV-infected patients studied with radionuclide ventriculography. <i>American Heart Journal</i> , 2004 , 148, e18	4.9	
48	Long-term effects of protease-inhibitor-based combination therapy. <i>Lancet, The</i> , 2004 , 363, 900; author reply 900-1	4.0	1
47	HIV infection, highly active antiretroviral therapy and the cardiovascular system. <i>Cardiovascular Research</i> , 2003 , 60, 87-95	9.9	27
46	The pavia consensus statement. <i>Aids</i> , 2003 , 17 Suppl 1, S170-9	3.5	32
45	Incidence of the involvement of the cardiovascular system in HIV infection. <i>Aids</i> , 2003 , 17, S46-S50	3.5	46
44	Vasculitic syndromes in HIV-infected patients. <i>Advances in Cardiology</i> , 2003 , 40, 185-96		4
43	Guidelines for the prevention and management of cardiovascular complications in HIV-infected patients receiving HAART: The Pavia Consensus Statement. <i>Advances in Cardiology</i> , 2003 , 40, 226-32		2
42	Clinical and biological insights in HIV-associated cardiovascular disease in the era of highly active antiretroviral therapy. <i>Aids</i> , 2003 , 17, S1-S3	3.5	0
41	Pathogenesis of HIV-associated heart disease. <i>Aids</i> , 2003 , 17 Suppl 1, S12-20	3.5	26

40	Kawasaki-like syndromes and other vasculitic syndromes in HIV-infected patients. <i>Aids</i> , 2003 , 17 Suppl 1, S77-82	3.5	28
39	Pathogenesis of HIV-associated cardiovascular disease. <i>Advances in Cardiology</i> , 2003 , 40, 49-70		3
38	Interactions between antiretroviral agents and drugs commonly used to treat cardiovascular diseases according to the Pavia Consensus Statement. <i>Advances in Cardiology</i> , 2003 , 40, 233-40		
37	HIV-associated lipodystrophy: pathogenesis and clinical features. <i>Advances in Cardiology</i> , 2003 , 40, 97-104		1
36	Evolution of the involvement of the cardiovascular system in HIV infection. <i>Advances in Cardiology</i> , 2003 , 40, 15-22		4
35	Highly active antiretroviral therapy and the cardiovascular system: the heart of the matter. <i>Pharmacology</i> , 2003 , 69, 177-9	2.3	6
34	An open-label, prospective, observational study of the incidence of coronary artery disease in patients with HIV infection receiving highly active antiretroviral therapy. <i>Clinical Therapeutics</i> , 2003 , 25, 2405-18	3.5	72
33	Good safety profile and efficacy of leucocyte interferon-alpha in combination with oral ribavirin in treatment-naive patients with chronic hepatitis C: a multicentre, randomised, controlled study. <i>BioDrugs</i> , 2003 , 17, 433-9	7.9	4
32	Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. <i>Current Pharmaceutical Design</i> , 2003 , 9, 1475-81	3.3	21
31	Incidence of the involvement of the cardiovascular system in HIV infection. <i>Aids</i> , 2003 , 17 Suppl 1, S46-50	5.5	19
30	Increased access to the emergency department for coronary heart disease of HIV-infected patients receiving highly active antiretroviral therapy. <i>Annals of Emergency Medicine</i> , 2002 , 40, 530-1	2.1	3
29	Cardiovascular manifestations of HIV infection. <i>Circulation</i> , 2002 , 106, 1420-5	16.7	143
28	Protease inhibitors and mortality among children and adolescents infected with HIV-1. <i>New England Journal of Medicine</i> , 2002 , 346, 1026-7; author reply 1026-7	59.2	2
27	HIV infection, antiretroviral therapy and cardiovascular risk. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002 , 9, 295-300		2
26	Consensus interferon for chronic hepatitis C patients with genotype 1 who failed to respond to, or relapsed after, interferon alpha-2b and ribavirin in combination: an Italian pilot study. <i>European Journal of Gastroenterology and Hepatology</i> , 2002 , 14, 477-83	2.2	18
25	. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , 2002 , 9, 295-300		3
24	Selenium Deficiency and HIV-Associated Cardiomyopathy. <i>Journal of the Royal Society of Medicine</i> , 2002 , 95, 57-57	2.3	1
23	Selenium deficiency and HIV-associated cardiomyopathy. <i>Journal of the Royal Society of Medicine</i> , 2002 , 95, 57	2.3	3

22	HIV-associated cardiomyopathy is not Keshan disease. <i>Journal of the Royal Society of Medicine</i> , 2002 , 95, 324	2.3	1
21	HIV infection and the cardiovascular system. <i>AIDS Reviews</i> , 2002 , 4, 93-103	1.5	25
20	Pathogenesis of HIV-associated cardiomyopathy. <i>Annals of the New York Academy of Sciences</i> , 2001 , 946, 57-81	6.5	34
19	HIV-associated coronary arteritis in a patient with fatal myocardial infarction. <i>New England Journal of Medicine</i> , 2001 , 344, 1799-800	59.2	57
18	Primary pulmonary hypertension in HIV patients: a systematic review. <i>Angiology</i> , 2001 , 52, 31-41	2.1	92
17	Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. <i>Journal of Hepatology</i> , 2001 , 35, 406-11	13.4	97
16	Pathogenesis of HIV-associated cardiovascular complications. <i>Lancet Infectious Diseases</i> , 2001 , 1, 115-24	25.5	95
15	HIV-associated cardiovascular complications: a new challenge for emergency physicians. <i>American Journal of Emergency Medicine</i> , 2001 , 19, 566-74	2.9	25
14	Heterosexual transmission of HIV-1 infection in UK. <i>Lancet</i> , 2001 , 358, 1458	40	
13	Cardiovascular manifestations of HIV infection. <i>Journal of the Royal Society of Medicine</i> , 2001 , 94, 384-90	2.3	50
12	Clinical course of cardiomyopathy in HIV-infected patients with or without encephalopathy related to the myocardial expression of tumour necrosis factor-alpha and nitric oxide synthase. <i>Aids</i> , 2000 , 14, 827-38	3.5	23
11	Evaluation of long-term efficacy of interferon alpha-2b and ribavirin in combination in naive patients with chronic hepatitis C: an Italian multicenter experience. Ribavirin-Interferon in Chronic Hepatitis Italian Group Investigators. <i>Journal of Hepatology</i> , 2000 , 33, 448-55	13.4	28
10	Intensity of myocardial expression of inducible nitric oxide synthase influences the clinical course of human immunodeficiency virus-associated cardiomyopathy. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS (GISCA). <i>Circulation</i> , 1999 , 100, 933-9	16.7	77
9	Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial. <i>American Journal of Medicine</i> , 1999 , 107, 112-8	2.4	63
8	Flumazenil for hepatic encephalopathy grade III and IVa in patients with cirrhosis: an Italian multicenter double-blind, placebo-controlled, cross-over study. <i>Hepatology</i> , 1998 , 28, 374-8	11.2	90
7	Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study. <i>American Journal of Gastroenterology</i> , 1998 , 93, 2445-51	0.7	47
6	Interferon-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-1 alone: an Italian multicenter, randomized, controlled, clinical study. <i>American Journal of Gastroenterology</i> , 1998 , 93, 2445-2451	0.7	34
5	Incidence of dilated cardiomyopathy and detection of HIV in myocardial cells of HIV-positive patients. Gruppo Italiano per lo Studio Cardiologico dei Pazienti Affetti da AIDS. <i>New England Journal of Medicine</i> , 1998 , 339, 1093-9	59.2	226

4	Cardiac involvement in the acquired immunodeficiency syndrome: a multicenter clinical-pathological study. Gruppo Italiano per lo Studio Cardiologico dei pazienti affetti da AIDS Investigators. <i>AIDS Research and Human Retroviruses</i> , 1998 , 14, 1071-7	1.6	143
3	Early impairment of systolic and diastolic function in asymptomatic HIV-positive patients: a multicenter echocardiographic and echo-Doppler study. The Gruppo Italiano Per lo Studio Cardiologico dei Pazienti Affetti da AIDS. <i>AIDS Research and Human Retroviruses</i> , 1996 , 12, 1559-63	1.6	35
2	Threshold Values of High-risk Echocardiographic Epicardial Fat Thickness. <i>Obesity</i> ,	8	1
1	Sequelae of Chronic Viral Hepatitis371-388		